Drug intelligence / Profile preview

IDP-126 Component A

Development stage: Unknown
Lead developer: Valeant Pharmaceuticals
Administration: Topical

Overview

IDP-126 Component A is an active pharmaceutical ingredient under development by Bausch Health Americas, Inc. It is identified as a component of IDP-126 Gel, a topical formulation being investigated for the treatment of acne vulgaris. Clinical trials for IDP-126 Gel, which includes IDP-126 Component A, have reached Phase 3 for this indication.

Targets

RARG (Retinoic acid receptor gamma)RARB (Retinoic acid receptor beta)C. acnes (Cutibacterium acnes)

Beyond the preview

Go deeper on IDP-126 Component A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDP-126 Component A.

Explore the full profile